Jefferies Cuts Price Target on Bristol-Myers Squibb (BMY) to $57; Reiterates hold
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Jefferies reiterated a Hold rating on Bristol-Myers Squibb Co. (NYSE: BMY), and cut the price target to $57.00 (from $69.00). Jefferies believes that the market could see worse than expected data from CM-026 and CM-568 as well as better than expected data from AZN's MYSTIC study and Roche's Chemo-IO studies in 2017.
Analyst Jeffrey Holford commented, "We see a difficult catalyst set for BMY with numerous competitor read outs in NSCLC as well as further downside to expectations for CM-026, CM-568 and CM-227. The market under-estimates AZN's MYSTIC study as well as Roche's Chemo-IO studies in our view. We model EPS up to 12% lower than consensus mid term. We strongly prefer risk-reward from Immuno-Oncology exposure through AZN (upgraded to Buy today) over BMY."
Shares of Bristol-Myers Squibb Co. closed at $55.66 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Waters Corp. (WAT) Following Revenue Miss
- Jefferies Cuts Price Target on Waddell & Reed Financial (WDR); Reiterates Hold
- New Oriental Education (EDU) PT Raised to $60 at Brean Capital
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!